Literature DB >> 18182742

A case of pancreatic cancer with formation of a mass mimicking alcoholic or autoimmune pancreatitis in a young man. Possibility of diagnosis by hypermethylation of pure pancreatic juice.

Koushiro Ohtsubo1, Hiroyuki Watanabe, Gensaku Okada, Tomoya Tsuchiyama, Hisatsugu Mouri, Yasushi Yamaguchi, Yoshiharu Motoo, Takashi Okai, Koji Amaya, Hirohisa Kitagawa, Tetsuo Ohta, Toshifumi Gabata, Koichiro Matsuda, Hideki Ohta, Norio Sawabu.   

Abstract

CONTEXT: Mass-forming pancreatitis can be divided into two distinct types: alcoholic and autoimmune. There have been some cases of an ambiguous diagnosis although care was taken to differentiate between alcoholic mass-forming pancreatitis, focal type autoimmune pancreatitis and pancreatic cancer. CASE REPORT: We report a case of pancreatic cancer mimicking alcoholic or autoimmune pancreatitis with the formation of a mass in a 32-year-old man with a history of heavy drinking. Although both serum immunoglobulin G and immunoglobulin G4 levels were normal, many serum auto-antibodies, including the antinuclear antibody, were detected. After he stopped drinking, abdominal computed tomography showed a pancreatic head mass 28 mm in diameter with little and weak enhancement in the early and delayed phases, respectively. Endoscopic retrograde cholangiopancreatography showed an obstruction of the main pancreatic duct in the pancreatic head and marked stenosis of the lower common bile duct. Although a percutaneous ultrasound-guided pancreatic biopsy demonstrated no evidence of autoimmune pancreatitis, he was treated with prednisolone to test the efficacy of steroid therapy. However, the pancreatic mass became enlarged after steroid therapy, and he underwent surgery during which the mass was found to be pancreatic cancer. Although the patient was treated with gemcitabine, he died 5 months after surgery. We retrospectively assessed DNA hypermethylation in the patient's pure pancreatic juice obtained on admission. We observed hypermethylation of the cancer-specific gene tissue factor pathway inhibitor 2 (TFPI2).
CONCLUSION: This finding suggests that if the DNA hypermethylation of pure pancreatic juice had been assayed before steroid therapy, it would have supported the diagnosis of pancreatic cancer, and steroid therapy could have been avoided.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18182742

Source DB:  PubMed          Journal:  JOP        ISSN: 1590-8577


  6 in total

1.  A case of pancreatic carcinoma with suspected autoimmune pancreatitis.

Authors:  Hiroyuki Matsubayashi; Kazuya Matsunaga; Katsuhiko Uesaka; Akira Fukutomi; Keiko Sasaki; Hiroyoshi Furukawa; Hiroyuki Ono
Journal:  Clin J Gastroenterol       Date:  2008-12-02

2.  Review of diagnostic criteria for autoimmune pancreatitis; for establishment of international criteria.

Authors:  Isao Nishimori; Saburo Onishi; Makoto Otsuki
Journal:  Clin J Gastroenterol       Date:  2008-03-19

3.  Utility of preoperative dynamic magnetic resonance imaging of the pancreas in diagnosing tumor-forming pancreatitis that mimics pancreatic cancer: report of a case.

Authors:  Tamotsu Kuroki; Yoshitsugu Tajima; Noritsugu Tsuneoka; Tomohiko Adachi; Takashi Kanematsu
Journal:  Surg Today       Date:  2009-12-29       Impact factor: 2.549

4.  Histopathologically proven autoimmune pancreatitis mimicking neuroendocrine tumor or pancreatic cancer.

Authors:  Shinji Onda; Tomoyoshi Okamoto; Masaru Kanehira; Shuichi Fujioka; Tohru Harada; Hiroshi Hano; Masaharu Fukunaga; Katsuhiko Yanaga
Journal:  Case Rep Gastroenterol       Date:  2012-01-20

5.  Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer.

Authors:  Marion Lavergne; Marie-Lise Jourdan; Claire Blechet; Serge Guyetant; Alain Le Pape; Nathalie Heuze-Vourc'h; Yves Courty; Stephanie Lerondel; Julien Sobilo; Sophie Iochmann; Pascale Reverdiau
Journal:  FEBS Open Bio       Date:  2013-06-27       Impact factor: 2.693

6.  TFPI-2 silencing increases tumour progression and promotes metalloproteinase 1 and 3 induction through tumour-stromal cell interactions.

Authors:  Guillaume Gaud; Sophie Iochmann; Audrey Guillon-Munos; Benjamin Brillet; Stéphanie Petiot; Florian Seigneuret; Antoine Touzé; Nathalie Heuzé-Vourc'h; Yves Courty; Stéphanie Lerondel; Yves Gruel; Pascale Reverdiau
Journal:  J Cell Mol Med       Date:  2011-02       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.